Description: Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Home Page: www.molecularpartners.com
MOLN Technical Analysis
Wagistrasse 14
Schlieren,
8952
Switzerland
Phone:
41 44 755 77 00
Officers
| Name | Title |
|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Exec. VP of Projects & Member of Management Board |
| Mr. Andreas Emmenegger E.M.B.A. | Advisor |
| Mr. Alexander Zurcher | COO & Member of Management Board |
| Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA | Chief Medical Officer & Member of Management Board |
| Ms. Renate Gloggner | Exec. VP of People & Community and Member of Management Board |
| Mr. Daniel Steiner Ph.D. | Sr. VP of Research |
| Mr. Seth D. Lewis | Sr. VP of Investor Relations, Communications & Strategy |
| Mr. Michael Pitzner | Gen. Counsel, Compliance Officer & Sr. VP of Legal |
| Mr. Thomas Schwerzmann | VP of HR |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 1.7775 |
|---|---|
| Trailing PE: | 1.7196 |
| Price-to-Book MRQ: | 0.9451 |
| Price-to-Sales TTM: | 1.3065 |
| IPO Date: | 2021-06-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 163 |